GLPG - Galapagos NV ADR - Stock Price & Dividends
Exchange: USA Stocks • Country: Belgium • Currency: USD • Type: Common Stock • ISIN: US36315X1019
Cancer, Immune Disorder, Oncology, Immunology, Gene Therapies, CAR-T
Galapagos NV is a biotechnology company that specializes in developing innovative medicines, primarily focusing on oncology and immunology. With a strong presence in the United States and Europe, the company is committed to improving the lives of patients suffering from severe diseases.
The company's pipeline is robust, with several promising products in various stages of development. One of its lead candidates, GLPG3667, has successfully completed a phase 1b trial. Additionally, Galapagos is advancing three CAR-T (Chimeric Antigen Receptor T-cell) product candidates, including GLPG5101, GLPG5201, and GLPG5301, which are being evaluated in phase 1/2 trials for the treatment of relapsed/refractory non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma, respectively. These CAR-T products are manufactured at the point-of-care, which enables faster and more efficient treatment.
Galapagos has established strategic collaborations with leading pharmaceutical companies, including Gilead Sciences, Inc. and AbbVie S.à r.l. These partnerships enable the company to leverage its expertise in drug discovery and development, while also gaining access to additional resources and expertise.
Founded in 1999, Galapagos NV is headquartered in Mechelen, Belgium, and has a strong commitment to innovation and patient care. For more information, please visit the company's website at https://www.glpg.com.
Drawdown (Underwater) Chart
GLPG Stock Overview
| Market Cap in USD | 1,717m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2005-05-06 |
GLPG Stock Ratings
| Growth 5y | -74.0 |
| Fundamental | -49.3 |
| Dividend | 0.00 |
| Rel. Performance vs Sector | -4.57 |
| Analysts | 3.29/5 |
| Fair Price Momentum | 18.58 USD |
| Fair Price DCF | - |
GLPG Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
GLPG Growth Ratios
| Growth 12m | -34.29% |
| Growth Correlation 12m | -55% |
| Growth Correlation 3m | -49% |
| CAGR 5y | -31.27% |
| CAGR/Mean DD 5y | -0.48 |
| Sharpe Ratio 12m | -1.64 |
| Alpha vs SP500 12m | -54.71 |
| Beta vs SP500 5y weekly | 0.97 |
| ValueRay RSI | 82.47 |
| Volatility GJR Garch 1y | 30.73% |
| Price / SMA 50 | 2.81% |
| Price / SMA 200 | -17.58% |
| Current Volume | 52k |
| Average Volume 20d | 112.6k |
External Links for GLPG Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of July 27, 2024, the stock is trading at USD 27.48 with a total of 52,003 shares traded.
Over the past week, the price has changed by +5.05%, over one month by +9.31%, over three months by -4.45% and over the past year by -35.11%.
According to ValueRays Forecast Model, GLPG Galapagos NV ADR will be worth about 20.7 in July 2025. The stock is currently trading at 27.48. This means that the stock has a potential downside of -24.85%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 40.9 | 48.9 |
| Analysts Target Price | 46.9 | 70.6 |
| ValueRay Target Price | 20.7 | -24.9 |